Download et al - epgonline.org

Traditional levodopa – strengths I
Bracco, F., Battaglia A., Chouza C. et al. The long-acting dopamine
receptor agonist cabergoline in early Parkinson's disease: final results
of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 2004;
18(11): 733–746.
Hoehn, M. M. and Yahr M. D. Parkinsonism: onset, progression, and
mortality. Neurology 1967; 17(5): 427–442.
Hoehn, M. M. and Elton R. L. Low dosages of bromocriptine added to
levodopa in Parkinson's disease. Neurology 1985; 35(2): 199–206.
Hoehn, M. M. The natural history of Parkinson's disease in the prelevodopa and post-levodopa eras. Neurol Clin 1992; 10(2): 331–339.
Holloway, R. G., Shoulson I., Fahn S. et al. Pramipexole vs levodopa
as initial treatment for Parkinson disease: a 4-year randomized
controlled trial. Arch Neurol 2004; 61(7): 1044–1053.
Oertel, W. H., Wolters E., Sampaio C. et al. Pergolide versus levodopa
monotherapy in early Parkinson's disease patients: The PELMOPET
study. Mov Disord 2006; 21(3): 343–353.
Traditional levodopa – strengths II
Olanow, C. W., Y. Agid, Y. Mizuno et al. Levodopa in the treatment of
Parkinson's disease: current controversies. Mov Disord 2004a; 19(9):
997–1005.
Parkinson Study Group. Safety and efficacy of pramipexole in early
Parkinson disease. A randomized dose-ranging study. JAMA 1997a;
278(2): 125–130.
Parkinson Study Group. Pramipexole vs levodopa as initial treatment
for Parkinson disease: A randomized controlled trial. JAMA 2000;
284(15): 1931–1938.
Poewe, W. H. and G. K. Wenning. The natural history of Parkinson's
disease. Neurology 1996; 47(6 Suppl 3): S146–152.
Rascol, O., Brooks D. J., Korczyn A. D. et al. (056 Study Group). A fiveyear study of the incidence of dyskinesia in patients with early
Parkinson's disease who were treated with ropinirole or levodopa. N
Engl J Med 2000; 342(20): 1484–1491.
Weintraub, D., Siderowf A. D., Potenza M. N. et al. Association of
dopamine agonist use with impulse control disorders in Parkinson’s
disease. Arch Neurol 2006; 63(7): 969–973.
Traditional levodopa – limitations of pulsatile delivery
Obeso, J. A., Rodriguez-Oroz M. C., Chana P. et al. The evolution and
origin of motor complications in Parkinson's disease. Neurology 2000;
55(11 Suppl 4): S13–S20.
Olanow, C. W., Obeso J. A. and Stocchi F. Continuous dopaminereceptor treatment of Parkinson's disease: scientific rationale and
clinical implications. Lancet Neurol 2006; 5(8): 677–687.
Stacy, M., Bowron A., Guttman M. et al. Identification of motor and
nonmotor wearing-off in Parkinson's disease: comparison of a patient
questionnaire versus a clinician assessment. Mov Disord 2005; 20(6):
726–733.
Sub-optimal delivery with disease progression
de la Fuente-Fernandez, R., Lu J. Q., Sossi V. et al. Biochemical
variations in the synaptic level of dopamine precede motor fluctuations
in Parkinson's disease: PET evidence of increased dopamine turnover.
Ann Neurol 2001; 49(3): 298–303.
Henry, B., Duty S., Fox S. H. et al. Increased striatal pre-proenkephalin
B expression is associated with dyskinesia in Parkinson's disease. Exp
Neurol 2003; 183(2): 458–468.
Olanow, C. W., Obeso J. A. and Stocchi F. Continuous dopaminereceptor treatment of Parkinson's disease: scientific rationale and
clinical implications. Lancet Neurol 2006; 5(8): 677–687.
Optimization of levodopa delivery I
Fariello, R. G. Pharmacodynamic and pharmacokinetic features of
cabergoline. Rationale for use in Parkinson's disease. Drugs 1998; 55
(Suppl 1): 10–16.
Grosset, K. A., Bone I. and Grosset D. G.. Suboptimal medication
adherence in Parkinson's disease. Mov Disord 2005; 20(11): 1502–
1507.
Koller, W. C., Hutton J. T., Tolosa E. et al. Immediate-release and
controlled-release carbidopa/levodopa in PD: a 5-year randomized
multicenter study. Carbidopa/Levodopa Study Group. Neurology 1999;
53(5): 1012–1019.
National Institute for Clinical Excellence (2006). NICE clinical guideline:
Parkinson's disease: diagnosis and management in primary and
secondary care. http://guidance.nice.org.uk/CG35 Last accessed
March 2007.
Optimization of levodopa delivery II
Nyholm, D., Lennernas H., Gomes-Trolin C. et al. Levodopa
pharmacokinetics and motor performance during activities of daily living
in patients with Parkinson's disease on individual drug combinations.
Clin Neuropharmacol 2002; 25(2): 89–96.
Stocchi, F., Battaglia G., Vacca L. et al. Clinical models of continuous
dopaminergic stimulation. Movement Disorders 2004; 19(Suppl 9):
S435.
Stocchi, F., Vacca L., Ruggieri S. et al. Intermittent vs continuous
levodopa administration in patients with advanced Parkinson disease: a
clinical and pharmacokinetic study. Arch Neurol 2005; 62(6): 905–910.
Stocchi, F. The levodopa wearing-off phenomenon in Parkinson's
disease: pharmacokinetic considerations. Expert Opin Pharmacother
2006; 7(10): 1399–1407.
Stalevo and its benefits I
Brooks, D. J. and Sagar H. Entacapone is beneficial in both fluctuating
and non-fluctuating patients with Parkinson's disease: a randomised,
placebo controlled, double blind, six month study. J Neurol Neurosurg
Psychiatry 2003; 74(8): 1071–1079.
Findley, L. J., Lees A., Apajasalo M. et al. Cost-effectiveness of
levodopa/carbidopa/entacapone (Stalevo) compared to standard care
in UK Parkinson's disease patients with wearing-off. Curr Med Res
Opin 2005; 21(7): 1005–1014.
Goetz, C. G., Stebbins G. T. and Blasucci L. M. Differential progression
of motor impairment in levodopa-treated Parkinson's disease. Mov
Disord 2000; 15(3): 479–484.
Gordin, A., Kaakkola S. and Teravainen H. Clinical advantages of
COMT inhibition with entacapone - a review. J Neural Transm 2004;
111(10–11): 1343–1363.
Stalevo and its benefits II
Larsen, J. P., Worm-Petersen J., Siden A. et al. The tolerability and
efficacy of entacapone over 3 years in patients with Parkinson's
disease. Eur J Neurol 2003; 10(2): 137–146.
Muller, T., Erdmann C., Muhlack S. et al. Inhibition of catechol-Omethyltransferase contributes to more stable levodopa plasma levels.
Mov Disord 2006; 21(3): 332–336.
Myllyla, V., Kultalahti E. R. V., Haapaniemi H. et al. Twelve-month
safety of entacapone in patients with Parkinson's disease. Eur J Neurol
2001; 8(1): 53–60.
Nissinen, H., Kuoppamaki M. and Leinonen M.. Early initiation of
entacapone leads to superior 5-year efficacy compared to delayed
initiation in Parkinson’s disease patients receiving traditional
levodopa/DDCI therapy. Mov Disord, 2006; 12(Suppl 15): S593.
Stalevo and its benefits III
Poewe, W. The role of COMT inhibition in the treatment of Parkinson's
disease. Neurology 2004; 62(1 Suppl 1): S31–S38.
Poewe, W. H., Deuschl G., Gordin A. et al. Efficacy and safety of
entacapone in Parkinson's disease patients with suboptimal levodopa
response: a 6-month randomized placebo-controlled double-blind study
in Germany and Austria (Celomen study). Acta Neurol Scand 2002;
105(4): 245–255.
Parkinson Study Group. Entacapone improves motor fluctuations in
levodopa-treated Parkinson's disease patients. Ann Neurol 1997b;
42(5): 747–755.
Rinne, U. K., Larsen J. P., Siden A. et al. Entacapone enhances the
response to levodopa in parkinsonian patients with motor fluctuations.
Nomecomt Study Group. Neurology 1998; 51(5): 1309–1314.
Stalevo and its benefits IV
Sawle, G. V., Burn D. J., Morrish P. K. et al. The effect of entacapone
(OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for
levodopa therapy of Parkinson's disease. Neurology 1994; 44(7):
1292–1297.
Stocchi, F. The levodopa wearing-off phenomenon in Parkinson's
disease: pharmacokinetic considerations. Expert Opin Pharmacother
2006; 7(10): 1399–1407.
Stocchi, F., Vacca L., Ruggieri S. et al. Intermittent vs continuous
levodopa administration in patients with advanced Parkinson disease: a
clinical and pharmacokinetic study. Arch Neurol 2005; 62(6): 905–910.
UPDRS scale from www.mdvu.org/library/ratingscales/pdf/
Benefits of earlier optimization of levodopa delivery
Fahn, S. Does levodopa slow or hasten the rate of progression of
Parkinson's disease? J Neurol 2005; 252(Suppl 4): iv37–iv42.
Fahn, S., Oakes D., Shoulson I. et al. Levodopa and the progression of
Parkinson's disease. N Engl J Med 2004; 351(24): 2498–2508.
Nissinen, H., Kuoppamaki M. and Leinonen M. Early initiation of
entacapone leads to superior 5-year efficacy compared to delayed
initiation in Parkinson’s disease patients receiving traditional
levodopa/DDCI therapy. Mov Disord 2006; 21(Suppl13): S111.
Parkinson Study Group. A controlled, randomized, delayed-start study
of rasagiline in early Parkinson disease. Arch Neurol 2004; 61(4): 561–
566.
Schapira, A. H. and Obeso J. Timing of treatment initiation in
Parkinson's disease: a need for reappraisal? Ann Neurol 2006; 59(3):
559–562.
Future directions I
Hauser, R. The First-step study: a study to evaluate the effects of
intitiating a fixed dose of Stalevo or levodopa/carbidopa t.i.d. in early
PD patients requiring levodopa. Eur J Neurol 2006; 13(Suppl 2): 94.
Jenner, P., Jackson M., Rose S. et al. Coadministration of
levodopa/carbidopa/entacapone avoids dyskinesia induction in MPTPtreated primates with full or partial nigral lesions. Mov Disord 2006; 21
(Suppl 13): S73.
Maratos, E. C., Jackson M. J., Pearce R. K. et al. Antiparkinsonian
activity and dyskinesia risk of ropinirole and L-DOPA combination
therapy in drug naive MPTP-lesioned common marmosets (Callithrix
jacchus). Mov Disord 2001; 16(4): 631–641.
Future directions II
Olanow, C. W. The STRIDE-PD (Stalevo Reduction In Dyskinesia
Evaluation) Study: A Long-term, Controlled study to evaluate the effects
of initiating Stalevo or carbidopa/levodopa in early PD. Eur J Neurol
2006; 13(Suppl 2): 93.
Rascol, O., Brooks D. J., Korczyn A. D. et al. A five-year study of the
incidence of dyskinesia in patients with early Parkinson's disease who
were treated with ropinirole or levodopa. 056 Study Group. N Engl J
Med 2000; 342(20): 1484–1491.
Smith, L. A., Jackson M. J., Al-Barghouthy G. et al. Multiple small doses
of levodopa plus entacapone produce continuous dopaminergic
stimulation and reduce dyskinesia induction in MPTP-treated drugnaive primates. Mov Disord 2005; 20(3): 306–14.
STA2637; Item date April 2007